Business
AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline - AbbVie
Aliada's lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a potential best-in-class therapy for Alzheimer's disease Acquisition also allows AbbVie to utilize...
By: Abbvie.com
- Oct 29 2024
- 0
- 0 Views
- Aliada's lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-A) antibody, is a potential best-in-class therapy for Alzheimer's disease
- Acquisition also allows AbbVie to … [+6369 chars]
Share this page
Guest Posts by Easy Branches
